Roivant Sciences Ltd.(ROIV)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ROIV Roivant Sciences Ltd.

未开盘 11-10 16:00:00 EST

41.19

+0.52

+1.28%

盘后41.19

+0.000.00%

19:30 EST

最高41.37	最低39.88	成交量1,059万
今开40.60	昨收40.67	日振幅3.66%
总市值297.56亿	流通市值239.31亿	总股本7.22亿
成交额4.32亿	换手率1.82%	流通股本5.81亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":41.19,"timestamp":1794344400000,"preClose":40.67,"halted":0,"volume":10589924,"hourTrading":{"tag":"盘后","latestPrice":41.19,"preClose":41.19,"latestTime":"19:30 EST","volume":1004563,"amount":41377936.8398,"timestamp":1794357004942,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.012785837226456749,"floatShares":581000000,"shares":722406273,"eps":-0.486857,"marketStatus":"未开盘","change":0.52,"latestTime":"11-10 16:00:00 EST","open":40.6,"high":41.37,"low":39.88,"amount":432144723.05584,"amplitude":0.036636,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.486857,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1794387600000},"marketStatusCode":0,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":40.67,"preHourTrading":{"tag":"盘前","latestPrice":40.62,"preClose":40.67,"latestTime":"09:29 EST","volume":4168,"amount":169633.09856,"timestamp":1794320999999,"change":-0.05,"changeRate":-0.001229,"amplitude":0.088517},"postHourTrading":{"tag":"盘后","latestPrice":41.19,"preClose":41.19,"latestTime":"19:30 EST","volume":1004563,"amount":41377936.8398,"timestamp":1794357004942,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.998334,"impliedVol":0.3566,"impliedVolPercentile":0.239},"requestUrl":"/m/hq/s/ROIV/tweets","defaultTab":"tweets","newsList":[{"id":"1121244951","title":"异动解读｜Roivant Sciences Ltd.盘中上涨5.41%，财报与核心管线进展提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1121244951","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121244951?lang=zh_cn&edition=full","pubTime":"2026-11-09 22:42","pubTimestamp":1794235379,"startTime":"0","endTime":"0","summary":"11月9日，Roivant Sciences Ltd.盘中上涨5.41%，报40.72美元/股，成交额2794.52万美元。本次异动主要受财报与研发进展共振驱动。公司第二财季每股亏损0.27美元，略好于市场预期的亏损0.28美元；营收3510万美元，较上年同期的160万美元大增，且显著高于预期的430万美元；截至9月30日，公司持有现金、现金等价物、受限现金及有价证券合计42亿美元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报超预期，核心管线进展强劲","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124673574","title":"异动解读｜Roivant Sciences Ltd.盘前上涨5.45%，财报前新药进展提振市场情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1124673574","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124673574?lang=zh_cn&edition=full","pubTime":"2026-11-09 20:16","pubTimestamp":1794226600,"startTime":"0","endTime":"0","summary":"11月9日，Roivant Sciences Ltd.盘前上涨5.45%，报40.99美元/股，成交额3.69万美元。近期公司核心管线连续释放积极进展，成为股价异动的主要催化。brepocitinib在两项非感染性葡萄膜炎Ⅲ期试验中达到主要终点及关键次要终点；此前mosliciguat在PH-ILD的Ⅱ期研究中达到主要和次要终点，且已推进至Ⅲ期开发。与此同时，brepocitinib已于8月获FDA批准用于成人皮肌炎治疗并在美国上市，强化了市场对其商业化前景的预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前新药进展亮眼，股价盘前异动上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157500835","title":"异动解读｜Roivant Sciences Ltd.盘中上涨6.34%，财报前新药进展提振市场情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1157500835","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157500835?lang=zh_cn&edition=full","pubTime":"2026-11-07 04:50","pubTimestamp":1793998243,"startTime":"0","endTime":"0","summary":"11月7日，Roivant Sciences Ltd.盘中上涨6.34%，报38.925美元/股，成交额3.19亿美元。近期消息面上，公司核心管线持续释放积极进展。其brepocitinib在两项非感染性葡萄膜炎Ⅲ期试验中达到主要终点及关键次要终点；更早前，mosliciguat在PH-ILD的Ⅱ期研究中达到主要和次要终点，且公司已推进至Ⅲ期开发。此外，brepocitinib已于8月获FDA批准用于成人皮肌炎治疗并在美国上市。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前新药进展亮眼，Roivant盘中上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130347359","title":"财报前瞻 | Roivant Sciences Ltd.本季度营收预计小幅下降，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1130347359","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130347359?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:14","pubTimestamp":1793578448,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.将于2026年11月09日发布最新季度财报，市场关注其收入与利润的阶段性拐点及核心资产商业化进展。市场一致预期本季度Roivant Sciences Ltd.营收为4,109,180.00美元，同比下降40.85%；EBIT为-3.36亿美元，同比降幅20.81%；每股收益为-0.38美元，同比降幅13.51%。公司上季度披露对本季度的具体毛利率、净利率与调整后每股收益未见明确口径，若管理层在业绩会中更新将是关注重点。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | Roivant Sciences Ltd.本季度营收预计小幅下降，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183875724","title":"异动解读｜Roivant Sciences Ltd.盘中上涨5.7%，brepocitinib三期试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1183875724","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183875724?lang=zh_cn&edition=full","pubTime":"2026-10-21 21:36","pubTimestamp":1792589787,"startTime":"0","endTime":"0","summary":"10月21日，Roivant Sciences Ltd.盘中上涨5.7%，报36.43美元/股，成交额7210.95万美元。消息面上，公司宣布brepocitinib在两项针对非感染性葡萄膜炎的三期试验中达到主要终点，并同时达成关键次要终点，直接提振市场情绪。该药物为JAK1和TYK2小分子抑制剂，也是公司核心后期管线之一。此次三期结果落地，意味着其在自身免疫相关适应症上的临床推进取得新进展，较早前暂无明确催化的盘前异动拥有更清晰解释。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Roivant三期达主要终点，股价盘中拉升","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176489425","title":"异动解读｜Roivant Sciences Ltd.盘前上涨7.1%，暂无明确新催化落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1176489425","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176489425?lang=zh_cn&edition=full","pubTime":"2026-10-21 19:22","pubTimestamp":1792581758,"startTime":"0","endTime":"0","summary":"10月21日，Roivant Sciences Ltd.盘前上涨7.1%，报37.98美元/股，成交额55.01万美元。Roivant Sciences Ltd.所在的生物科技行业中，Moderna, Inc.跌0.05%，艾伯维公司跌0.2%，安进跌0.9%，吉利德科学跌0.43%，福泰制药跌0.9%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669485368","title":"Roivant（ROIV）跌2.93% 皮肤红斑狼疮试验失利","url":"https://stock-news.laohu8.com/highlight/detail?id=2669485368","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669485368?lang=zh_cn&edition=full","pubTime":"2026-09-23 20:06","pubTimestamp":1790165207,"startTime":"0","endTime":"0","summary":"金吾财讯 | Roivant Sciences 美股盘前股价承压，最新跌2.93%，报37.1美元。消息面上，Roivant旗下子公司Immunovant的在研药物IMVT-1402针对皮肤自身免疫疾病-皮肤红斑狼疮的概念验证临床试验宣告失败。公司公布的12周试验数据显示，这项纳入57名受试者的研究，未能达成基于皮肤红斑狼疮疾病面积与严重程度活动指数评分设定的主要终点。受本次试验结果以及皮肤红斑狼疮领域行业竞争影响，Immunovant将不再继续推进IMVT-1402项目。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/NmJhNzAzYmFlYjJhNGNmZDhhMTE1NWJmMTYxODM5M2UxMzU2NDM2MDM2MQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NmJhNzAzYmFlYjJhNGNmZDhhMTE1NWJmMTYxODM5M2UxMzU2NDM2MDM2MQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306391","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","ROIV","BK4588","IMVT","PTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195156658","title":"异动解读｜Roivant Sciences盘中上涨14.2%，核心管线Mosliciguat二期临床达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1195156658","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195156658?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:30","pubTimestamp":1788874228,"startTime":"0","endTime":"0","summary":"9月8日，Roivant Sciences盘中上涨14.2%，报39.9美元/股，成交额3711.26万美元。消息面上，公司旗下Pulmovant部门宣布其吸入式sGC激活剂Mosliciguat在间质性肺病相关肺动脉高压患者中开展的二期PHocus研究达到主要及次要终点。药物安全性良好，疗效持续改善。公司同时披露已启动Phrontier三期研究，推动Mosliciguat向注册阶段迈进。Roivant Sciences是一家生物制药公司，核心管线包括处于FDA审查阶段的brepocitinib、靶向FcRn的IMVT-1402以及Mosliciguat。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Roivant大涨，肺高压新药疗效亮眼","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192184963","title":"实验性肺病药物中期研究达主要终点 Roivant Sciences股价盘前飙升21.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192184963","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192184963?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:11","pubTimestamp":1788862270,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.股价在盘前交易中大涨21.1%，此前该公司宣布其研发的一款针对肺部疾病的实验性药物，在一项中期研究中成功达到了主要疗效终点。这一积极进展显著提振了市场信心，推动股价迅速走高。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","PTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103996547","title":"异动解读｜Roivant Sciences盘前上涨28.66%，核心管线Mosliciguat临床研究获积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1103996547","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103996547?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:06","pubTimestamp":1788861984,"startTime":"0","endTime":"0","summary":"9月8日，Roivant Sciences盘前上涨28.66%，报44.92美元/股，成交额14.04万美元。消息面上，公司宣布其吸入式sGC激活剂Mosliciguat在间质性肺病相关肺动脉高压患者中开展的Phocus研究取得积极结果，数据验证了药物的有效性。PH-ILD长期缺乏有效疗法，Mosliciguat的积极数据为该领域带来潜在突破。Roivant Sciences是一家生物制药公司，核心管线包括处于FDA审查阶段的brepocitinib、靶向FcRn的IMVT-1402以及本次获得积极数据的Mosliciguat。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Mosliciguat临床数据积极，Roivant盘前大涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102884849","title":"Roivant公布Mosliciguat治疗间质性肺病相关肺动脉高压（Ph-Ild）的Phocus研究积极结果，并披露正在进行的Phrontier III期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1102884849","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102884849?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:01","pubTimestamp":1788861671,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.今日宣布，其针对Mosliciguat在间质性肺病相关肺动脉高压患者中的Phocus研究取得了振奋人心的积极成果。与此同时，该公司还揭开了正在推进的Phrontier III期研究的面纱，这一举措标志着该候选药物在临床开发道路上又迈出了坚实一步。据悉，Phocus研究的数据不仅验证了药物的有效性，还为这一长期缺乏有效疗法的罕见病症带来了新的希望之光。值得注意的是，Phrontier III期研究的启动，无疑将进一步巩固Mosliciguat在该适应症领域的潜在治疗地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","PTH","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141500682","title":"Priovant宣布FDA批准Lisraya™（Brepocitinib）用于成人皮肌炎治疗；现已在美国上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1141500682","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141500682?lang=zh_cn&edition=full","pubTime":"2026-08-28 03:29","pubTimestamp":1787858949,"startTime":"0","endTime":"0","summary":"Priovant今日宣布，美国食品药品监督管理局（FDA）已正式批准Lisraya™（Brepocitinib）用于治疗成人皮肌炎患者。这一里程碑式的决定意味着该药物现已即刻在美国市场供应。\n皮肌炎是一种罕见的自身免疫性疾病，以肌肉无力和特征性皮疹为主要表现，长期以来困扰着众多患者。此次获批为这一患者群体带来了全新的治疗选择。\nLisraya™作为一种创新疗法，其获批上市标志着皮肌炎治疗领域取得了重大突破。该药物目前已可及，符合条件的患者将能够立即获得这一新的治疗方案的处方。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","PTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169456208","title":"《JAMA皮肤病学》发布Brepocitinib治疗皮肌炎3期VALOR试验皮肤特异性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1169456208","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169456208?lang=zh_cn&edition=full","pubTime":"2026-08-26 23:12","pubTimestamp":1787757130,"startTime":"0","endTime":"0","summary":"《JAMA皮肤病学》杂志正式刊发了Brepocitinib在皮肌炎治疗中的3期VALOR试验皮肤特异性结局数据。这项研究聚焦于皮肤相关症状的改善情况，为这一罕见自身免疫性疾病的治疗提供了新的临床证据。该试验结果此前已引起业界广泛关注，如今皮肤特异性数据的公布，进一步丰富了人们对Brepocitinib疗效维度的理解。皮肌炎以皮肤和肌肉炎症为特征，皮肤表现往往对患者生活质量造成显著影响，因此这一数据的发布具有重要临床意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","PTH","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187698206","title":"Roivant Sciences：Brepocitinib新药申请获批，皮肌炎产品预计2026年9月底前上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1187698206","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187698206?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:29","pubTimestamp":1786015777,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. 传来重磅消息。其研发的Brepocitinib，在针对皮肌炎的治疗上，已提交新药申请（NDA）。公司预计，该药物有望在2026年9月底前获得批准，并正式推向市场。这无疑是一个关键节点，标志着这家生物制药公司，在自身免疫疾病领域的布局迈出了坚实一步。皮肌炎作为一种罕见的自身免疫性疾病，一直缺乏有效的治疗手段。Brepocitinib若能如期获批，将为患者带来新的希望。目前，市场正密切关注这一进展，并期待其最终结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","PTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176010812","title":"财报前瞻｜Roivant Sciences Ltd.本季度营收预计大幅下滑，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1176010812","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176010812?lang=zh_cn&edition=full","pubTime":"2026-07-30 10:01","pubTimestamp":1785376902,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.计划于2026年08月06日发布财报，市场聚焦费用端收缩与在研管线推进节奏对利润和现金流的影响。根据一致预期，本季度Roivant Sciences Ltd.预计总营收为2.06百万美元，同比下降71.57%；预计调整后每股收益为-0.32美元，同比变化为-2.18%；预计EBIT为-3.07亿美元，同比改善19.95%。基于近六个月的公开研报与观点收集，机构整体对Roivant Sciences Ltd.的短期基本面持偏谨慎态度，看空与中性观点合计比例高于看多。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Roivant Sciences Ltd.本季度营收预计大幅下滑，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170932235","title":"Roivant Sciences 将于2026年8月6日公布第一财季业绩并更新业务动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1170932235","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170932235?lang=zh_cn&edition=full","pubTime":"2026-07-24 04:06","pubTimestamp":1784837181,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.（ROIV）计划于2026年8月6日（周四）发布截至同年6月30日的第一财季财务报告。届时，公司还将同步提供最新的业务进展动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","PTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150102941","title":"异动解读 | Roivant Sciences盘中大涨15.99%，财报及关节炎药物进展提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1150102941","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150102941?lang=zh_cn&edition=full","pubTime":"2026-05-21 01:05","pubTimestamp":1779296717,"startTime":"0","endTime":"0","summary":"生物制药公司Roivant Sciences Ltd.（ROIV）今日盘中股价大幅上涨15.99%，表现强劲。消息面上，公司公布了截至2026年3月31日的第四季度及全年财务业绩，并同步更新了业务进展。尽管第四季度营收低于市场预期，但公司披露的业务动态获得了市场的积极评价。其中，路透社的市场快讯特别指出，其关节炎药物初步显示出积极效果，这一进展是推动股价走高的关键因素。Roivant Sciences是一家通过构建技术平台来加速开发变革性药物的公司，此次财报与研发进展的披露，显著增强了投资者对其未来增长潜力的信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182026444","title":"异动解读｜Roivant Sciences盘中上涨11.1%，公布财年业绩及业务进展获市场积极反应","url":"https://stock-news.laohu8.com/highlight/detail?id=1182026444","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182026444?lang=zh_cn&edition=full","pubTime":"2026-05-20 21:40","pubTimestamp":1779284409,"startTime":"0","endTime":"0","summary":"5月20日，Roivant Sciences盘中上涨11.1%，报30.48美元/股，成交额3466.28万美元。消息面上，公司公布了截至3月31日的第四财季及全年财务业绩，并同步更新业务动态。尽管营收不及预期，但公司披露的业务进展获得市场积极反应，推动股价走强。Roivant Sciences是一家注册于百慕大的生物制药公司，通过构建技术平台和培养人才推出专注的生物制药及健康技术子公司，致力于更快开发变革性药物。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150457356","title":"异动解读｜Roivant Sciences盘前上涨8.12%，公布财年业绩及业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1150457356","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150457356?lang=zh_cn&edition=full","pubTime":"2026-05-20 19:38","pubTimestamp":1779277123,"startTime":"0","endTime":"0","summary":"5月20日，Roivant Sciences盘前上涨8.12%，报30.43美元/股，成交额170.13万美元。消息面上，公司公布了截至3月31日的第四财季及全年财务业绩。数据显示，第四财季持续运营每股收益为0.28美元，营收252万美元低于市场预期的382万美元。尽管营收不及预期，但公司同步披露的业务动态更新获得市场积极反应，推动股价走强。Roivant Sciences是一家注册于百慕大的生物制药公司，通过构建技术平台和培养人才推出专注的生物制药及健康技术子公司，致力于更快开发变革性药物。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174214400","title":"异动解读 | 公布财报及业务进展，Roivant Sciences盘前大涨9.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174214400","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174214400?lang=zh_cn&edition=full","pubTime":"2026-05-20 19:19","pubTimestamp":1779275955,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. (ROIV) 今日盘前股价大幅上涨9.89%，市场反应积极。消息面上，公司公布了截至2026年3月31日的第四季度及整个财年的财务业绩，并提供了最新的业务动态更新。这份财报和业务进展的披露，是推动股价在盘前交易时段走强的主要原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://roivant.com;investor.roivant.com","stockEarnings":[{"period":"1week","weight":0.1332},{"period":"1month","weight":0.1476},{"period":"3month","weight":0.1538},{"period":"6month","weight":0.3919},{"period":"1year","weight":0.9724},{"period":"ytd","weight":0.8742}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0332},{"period":"3month","weight":-0.0232},{"period":"6month","weight":0.014},{"period":"1year","weight":0.1218},{"period":"ytd","weight":0.1038}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Roivant Sciences Ltd.于2020年7月6日在百慕大注册成立。该公司是一家生物制药公司，旨在加速药物的开发和商业化。公司的研发管线包括brepocitinib（一种JAK1和TYK2小分子抑制剂，正在接受FDA审查用于治疗皮肌炎，并处于治疗非感染性葡萄膜炎、皮肤结节病和 lichen planopilaris的后期开发阶段）、IMVT-1402（一种针对FcRn的全人源单克隆抗体，正在开发用于治疗IgG介导的自身免疫适应症）以及mosliciguat（一种吸入式sGC激活剂，正在开发用于治疗间质性肺病相关的肺动脉高压）。公司通过创建灵活的子公司来推进其研发管线，以开发和商业化其药物和技术。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.071559},{"month":2,"riseRate":0.333333,"avgChangeRate":0.052607},{"month":3,"riseRate":0,"avgChangeRate":-0.087601},{"month":4,"riseRate":0.833333,"avgChangeRate":0.021573},{"month":5,"riseRate":0.5,"avgChangeRate":0.035469},{"month":6,"riseRate":0.833333,"avgChangeRate":0.042574},{"month":7,"riseRate":0.666667,"avgChangeRate":0.026843},{"month":8,"riseRate":0.666667,"avgChangeRate":0.010529},{"month":9,"riseRate":0.5,"avgChangeRate":0.020205},{"month":10,"riseRate":0.666667,"avgChangeRate":0.086096},{"month":11,"riseRate":0.833333,"avgChangeRate":0.037936},{"month":12,"riseRate":0.8,"avgChangeRate":0.23185}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Roivant Sciences Ltd.(ROIV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Roivant Sciences Ltd.(ROIV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}